Is Special Opportunities Fund, Inc. (SPE) a Buy, Sell, or Hold?
NYSE : SPE
Special Opportunities Fund, Inc. — News
$13.39 USD
-$0.12 (-0.89%)
- Volume
- 24.21K
- Average Volume
- 34.54K
- Market Capitalization
- $142.24M
- P/E Ratio
- 7.70
- Dividend Yield
- 20.12%
- Price Target
- Year High
- $15.99
- Year Low
- $13.14
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.74
- Current Ratio
- $0.00
| Source | Headline |
|---|---|
|
SPE: Discount Gets Even Deeper And More Attractive
The Special Opportunities Fund trades at a deep discount that has recently gotten deeper, making it a compelling 'Buy' despite recent underperformance. SPE's portfolio is heavily weighted toward other discounted CEFs and SPACs, providing diversification, but a couple of names have resulted in muted returns so far this year. That can be important because the fund's distribution policy is based on an 8% reset, and the fund has not been keeping up with the returns needed. seekingalpha.com - 2026-07-20 10:19:27 |
|
Special Opportunities Fund Announces Distributions For Third Quarter of 2026
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Special Opportunities Fund, Inc. (NYSE: SPE) (the “Fund”) today announced that the Fund's Board of Directors (the “Board”) has declared the next three monthly distributions under the Fund's managed distribution plan. globenewswire.com - 2026-07-01 10:41:00 |
|
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi gurufocus.com - 2026-06-13 07:00:00 |
